Eris Lifesciences Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Thu Apr 23 2026

The Eris Lifesciences share price target 2026 stands at Rs 1,102-1,282 as per analyst consensus — implying 20-39% upside from the current CMP of Rs 922. Investors tracking the Eris Lifesciences share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Eris Lifesciences (ERIS) achieves or misses this 12-month target. This article covers every dimension of the Eris Lifesciences share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Eris Lifesciences on Univest.

Table of Contents

Eris Lifesciences Share Price Overview — April 2026

Company	Eris Lifesciences
NSE Symbol	ERIS
Sector	Pharma / Chronic Therapy / Lifestyle Diseases
CMP April 2026	Rs 922
52-Week High	Rs 1,302
52-Week Low	Rs 752
Market Cap	Rs 12,600 Cr
Trailing P/E	22x
Dividend FY26	Rs 5
Promoter Holding	52.6%
FII Holding	14.8%
12M Analyst Target	Rs 1,102-1,282
Upside from CMP	20-39%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Eris Lifesciences price, FII/DII flows and analyst targets on the Univest Screener.

What Is Eris Lifesciences?

Get Free Analyst Research on Eris Lifesciences — Tap Here.

Eris Lifesciences (NSE: ERIS) focuses on chronic therapy — diabetes, cardiovascular, CNS. Consistent 20%+ EBITDA margins through brand investment and doctor relationships. FY26 revenue Rs 1,800+ crore with chronic portfolio growing 18% YoY.

Budget 2026-27 Impact on Pharma

Budget 2026’s expanded insurance for chronic disease treatment directly benefits Eris — 70%+ revenues from diabetes and cardiovascular prescriptions.

Eris Lifesciences share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 1,102	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 1,102-1,282	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 752 zone	FY27 miss and extended FII selling

Compare Eris Lifesciences with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Eris Lifesciences share price target 2026

1. India Pharma Sector — Structural Growth Tailwind

India’s Pharma sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Eris Lifesciences’s market position within this sector creates compounding runway that underpins the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Eris Lifesciences to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Eris Lifesciences holds a structural competitive moat in its Pharma segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Eris Lifesciences share price target 2026 of Rs 1,102-1,282.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Eris Lifesciences’s borrowing costs and stimulates end-customer demand for Pharma products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Eris Lifesciences share price target 2026 of Rs 1,102-1,282 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Eris Lifesciences’s Pharma business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Eris Lifesciences share price target 2026 bull case.

Download the Univest iOS App or Android App for live Eris Lifesciences alerts and SEBI-registered research.

5 Risks That Could Impact the Eris Lifesciences share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Eris Lifesciences. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282.

2. Valuation at 22x Requires Consistent Execution

At 22x trailing P/E, Eris Lifesciences is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Eris Lifesciences share price target 2026. The Rs 752 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in Pharma

Domestic and global competitors are investing aggressively in Eris Lifesciences’s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Eris Lifesciences share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Eris Lifesciences share price target 2026 of Rs 1,102-1,282.

5. FII Selling Risk — 14.8% Institutional Holding

With 14.8% FII ownership, Eris Lifesciences is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Eris Lifesciences share price target 2026 analyst consensus of Rs 1,102-1,282.

Eris Lifesciences Bull Case vs Bear Case — Eris Lifesciences share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	1,282	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 1,102-1,282	High	FY27 in-line earnings, stable macro
Bear Case	Rs 752 zone	Low	FY27 guidance cut, prolonged FII selling

Eris Lifesciences Share Price Reference Table

NSE Symbol	ERIS
CMP	Rs 922
52-Week High	Rs 1,302
52-Week Low	Rs 752
Market Cap	Rs 12,600 Cr
P/E	22x
Promoter	52.6%
FII	14.8%
Dividend FY26	Rs 5
Short-Term Target	Rs 1,102
12M Target	Rs 1,102-1,282
Upside	20-39%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Eris Lifesciences share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 1,106	FY27 earnings recovery and Pharma sector leadership
YES Securities	Buy	Rs 1,124	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 1,060	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Eris Lifesciences.

How to Invest in Eris Lifesciences — 5 Steps

Step 1: Research on the Univest Screener

Search ERIS on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Eris Lifesciences share price target 2026.

Step 2: Identify Entry Level

Eris Lifesciences at Rs 922 has key support near Rs 752. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Eris Lifesciences share price target 2026 recovery is Rs 1,102.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 1,282 — the bull case for the Eris Lifesciences share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Eris Lifesciences share price target 2026.

Conclusion — Eris Lifesciences share price target 2026

Eris Lifesciences (ERIS) at Rs 922 offers 20-39% potential upside to the 12-month Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. The bull case to 1,282 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 752 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Eris Lifesciences at current levels presents a monitored entry opportunity. For more Eris Lifesciences share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Eris Lifesciences share price target 2026

Q: What is Eris Lifesciences share price target for 2026?

The 12-month Eris Lifesciences share price target 2026 analyst consensus is Rs 1,102-1,282 — implying 20-39% upside from CMP Rs 922. Bull case: 1,282. Bear case: Rs 752 zone. Track the live Eris Lifesciences share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Eris Lifesciences a good buy at Rs 922?

This article does not constitute investment advice. At Rs 922, Eris Lifesciences offers 20-39% upside to the Eris Lifesciences share price target 2026 consensus of Rs 1,102-1,282. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Eris Lifesciences 52-week high and low?

Eris Lifesciences’s 52-week high is Rs 1,302 and 52-week low is Rs 752. At the current CMP of Rs 922, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Eris Lifesciences share price target 2026 thesis.

Q: What sector is Eris Lifesciences (ERIS) in?

Eris Lifesciences operates in the Pharma / Chronic Therapy / Lifestyle Diseases sector. India’s Pharma sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Eris Lifesciences share price target 2026 bull case.

Q: What are the main risks for the Eris Lifesciences share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at 22x requiring consistent execution, competition in Pharma, input cost volatility, and FII selling pressure (14.8% holding). Monitor quarterly earnings closely.

Q: What is Eris Lifesciences’s market cap?

Eris Lifesciences has a market cap of Rs 12,600 Cr as of April 2026. At the Eris Lifesciences share price target 2026 of Rs 1,102-1,282, the implied market cap would reflect 20-39% appreciation on the current base.

Q: What is Eris Lifesciences dividend for FY26?

Eris Lifesciences’s FY26 dividend is Rs 5. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Eris Lifesciences share price target 2026 capital appreciation potential.

Q: How to buy Eris Lifesciences shares?

Buy Eris Lifesciences (ERIS) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 752 support zone, and download the Univest App for SEBI-registered research on the Eris Lifesciences share price target 2026.